| Popis: |
BACKGROUND: Tepotinib, a highly selective, oral, once-daily MET inhibitor, has recently been approved for treatment of metastatic MET exon 14 skipping non-small cell lung cancer. OBJECTIVES: This article provides nurse-specific recommendations for identification and management of tepotinib adverse events (AEs). METHODS: Guidance on monitoring and proactive/reactive AE management was developed based on published literature and real-world nursing experience. Case studies of VISION trial participants were summarized to illustrate key principles. FINDINGS: Tepotinib AEs are generally mild/moderate, manageable, and mostly include peripheral edema, hypoalbuminemia, nausea, diarrhea, and creatinine increase. Alongside supportive care, tepotinib interruption and dose reduction is recommended for Grade 3 AEs. Peripheral edema may be easier to manage if recognized early, before it becomes more established and difficult to treat. Proactive monitoring is therefore crucial and should include regular measurement of body weight and limb circumference, and limb inspection for swelling or skin erosion. Treatment interruption (including frequent, short treatment holidays) should be considered early for peripheral edema. Gastrointestinal AEs are typically transient, and may be limited by administration with food and effectively managed with antidiarrheals/antiemetics. Through effective patient education, proactive monitoring, and coordination of multidisciplinary teamworking, nurses play a key role in managing the most common tepotinib AEs. |
